Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression

dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.contributorUniv Toronto
dc.contributorDeakin Univ
dc.contributorChulalongkorn Univ
dc.creatorNoto, Cristiano [UNIFESP]
dc.creatorRizzo, Lucas Bortolotto [UNIFESP]
dc.creatorMansur, Rodrigo Barbachan [UNIFESP]
dc.creatorMcIntyre, Roger S.
dc.creatorMaes, Michael
dc.creatorBrietzke, Elisa [UNIFESP]
dc.date.accessioned2016-01-24T14:35:01Z
dc.date.accessioned2022-10-07T20:29:30Z
dc.date.available2016-01-24T14:35:01Z
dc.date.available2022-10-07T20:29:30Z
dc.date.created2016-01-24T14:35:01Z
dc.date.issued2014-01-01
dc.identifierNeuroimmunomodulation. Basel: Karger, v. 21, n. 2-3, p. 131-139, 2014.
dc.identifier1021-7401
dc.identifierhttp://repositorio.unifesp.br/handle/11600/37208
dc.identifier10.1159/000356549
dc.identifierWOS:000331488100010
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4018708
dc.description.abstractIn the last decades convergent findings from several lines of evidence has revealed a robust association between major depressive disorder (MDD) and inflammatory pathways. Despite this, the translation of these findings into new and better treatments for MDD has not occurred. the objective of this study is to comprehensively review what is already known with reasonable certainty on inflammatory pathways in MDD, to clarify some points that have been insufficiently studied and to discuss the implications of these findings for future studies targeting inflammatory pathways as a therapeutic tool for individuals with MDD. (C) 2014 S. Karger AG, Basel
dc.languageeng
dc.publisherKarger
dc.relationNeuroimmunomodulation
dc.rightshttp://www.karger.com/Services/RightsPermissions
dc.rightsAcesso aberto
dc.subjectDepression
dc.subjectInflammation
dc.subjectCytokines
dc.titleTargeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression
dc.typeArtigo


Este ítem pertenece a la siguiente institución